Drugs / KI1001
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT02087722 | Aug 2013 → Jan 2014 | insomnia | Kuhnil Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT01450228 | Mar 2011 → Mar 2012 | sleep disorder, initiating and maintaining sleep | Kuhnil Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | KI1001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01450228 ↗ |
| Known as | Circadin | “KI1001(Circadin®, Prolonged release tablet which contains melatonin) has showed its efficacy to improve sleep quality in over 55 years old primary insomnia patients.” NCT01450228 ↗1“KI1001(Circadin®, Prolonged release tablet which contains melatonin)” NCT02087722 ↗ |